151. TERT promotor status does not add prognostic information in IDH-wildtype glioblastomas fulfilling other diagnostic WHO criteria:A report of the RANO resect group
- Author
-
Karschnia, Philipp, Young, Jacob S., Dono, Antonio, Häni, Levin, Juenger, Stephanie T., Sciortino, Tommaso, Bruno, Francesco, Teske, Nico, Morshed, Ramin A., Haddad, Alexander F., Zhang, Yalan, Stoecklein, Sophia, Vogelbaum, Michael A., Beck, Juergen, Tandon, Nitin, Hervey-Jumper, Shawn, Molinaro, Annette M., Rudà, Roberta, Bello, Lorenzo, Schnell, Oliver, Esquenazi, Yoshua, Ruge, Maximilian I., Grau, Stefan J., Van Den Bent, Martin, Weller, Michael, Berger, Mitchel S., Chang, Susan M., Tonn, Joerg Christian, Karschnia, Philipp, Young, Jacob S., Dono, Antonio, Häni, Levin, Juenger, Stephanie T., Sciortino, Tommaso, Bruno, Francesco, Teske, Nico, Morshed, Ramin A., Haddad, Alexander F., Zhang, Yalan, Stoecklein, Sophia, Vogelbaum, Michael A., Beck, Juergen, Tandon, Nitin, Hervey-Jumper, Shawn, Molinaro, Annette M., Rudà, Roberta, Bello, Lorenzo, Schnell, Oliver, Esquenazi, Yoshua, Ruge, Maximilian I., Grau, Stefan J., Van Den Bent, Martin, Weller, Michael, Berger, Mitchel S., Chang, Susan M., and Tonn, Joerg Christian
- Abstract
In IDH-wildtype glioblastomas which meet the histopathological or molecular diagnosis criteria, it remains unclear whether the presence of TERT promotor mutations provides additional prognostic information. Based on a multicenter cohort of 466 IDH-wildtype glioblastomas (including 396 with and 70 patients without TERT promotor mutations), we found that TERT promotor mutations were neither associated with progression-free survival nor overall survival. This held true in various treatment-based or molecular subgroups. This argues against standardized analysis for TERT promotor mutation status for the purpose of prognostic or therapeutic relevance in newly diagnosed IDH-wildtype glioblastoma that otherwise meets the histopathological and molecular diagnosis criteria.
- Published
- 2022